Wang I-Kuan, Lu Chi-Yu, Lin Cheng-Li, Liang Chih-Chia, Yen Tzung-Hai, Liu Yao-Lung, Sung Fung-Chang
Graduate Institute of Clinical Medical Science, China Medical University College of Medicine, Taichung, Taiwan; Department of Internal Medicine, China Medical University College of Medicine, Taichung, Taiwan; Division of Nephrology, China Medical University Hospital, Taichung, Taiwan.
Department of Biochemistry, College of Medicine Kaohsiung Medical University, Kaohsiung, Taiwan.
Int J Cardiol. 2016 Sep 1;218:219-224. doi: 10.1016/j.ijcard.2016.05.036. Epub 2016 May 14.
The purpose of the study was to compare the risk of de novo cardiovascular disease (CVD) between hemodialysis (HD) and peritoneal dialysis (PD) in patients with incident end-stage renal disease (ESRD).
From a Taiwanese universal insurance claims database, we identified 45309 incident ESRD patients without preexisting CVD from 2000 to 2010. Using the propensity score matching method, we included 6516 patients in HD and PD groups, respectively. All patients were followed up until the end of 2011. The Cox proportional hazards regression model was employed to calculate the impact of dialysis modality on the risk of new onset cardiovascular events including ischemic heart disease, and congestive heart failure (CHF).
No difference was observed in the overall risk of de novo ischemic heart disease between the propensity score-matched HD and PD groups (HD versus PD, adjusted hazard ratio [HR]: 1.03, 95% confidence interval [CI]: 0.86-1.22). However, HD was associated with a higher risk of de novo CHF (adjusted HR: 1.29, 95% CI: 1.13-1.47) than PD was. The risk of de novo CHF was particularly high in the first year under dialysis treatment for propensity score-matched HD patients, compared to PD patients.
No difference was observed in the overall risk of de novo major ischemic heart events between HD and PD patients. However, HD was associated with a higher risk of de novo CHF than PD in the first year under dialysis treatment.
本研究旨在比较初发终末期肾病(ESRD)患者中,血液透析(HD)和腹膜透析(PD)患者发生新发心血管疾病(CVD)的风险。
从台湾全民健康保险理赔数据库中,我们识别出2000年至2010年间45309例无既往CVD的初发ESRD患者。采用倾向得分匹配法,分别纳入HD组和PD组各6516例患者。所有患者随访至2011年底。采用Cox比例风险回归模型计算透析方式对包括缺血性心脏病和充血性心力衰竭(CHF)在内的新发心血管事件风险的影响。
倾向得分匹配的HD组和PD组之间,新发缺血性心脏病的总体风险无差异(HD组与PD组,调整后风险比[HR]:1.03,95%置信区间[CI]:0.86 - 1.22)。然而,HD组新发CHF的风险高于PD组(调整后HR:1.29,95%CI:1.13 - 1.47)。与PD患者相比,倾向得分匹配的HD患者在透析治疗的第一年新发CHF的风险特别高。
HD患者和PD患者之间,新发主要缺血性心脏事件的总体风险无差异。然而,在透析治疗的第一年,HD组新发CHF的风险高于PD组。